Published clinical trials have demonstrated varying levels of efficacy in individuals affected by RPE65-related LCA, severe early-childhood-onset retinal dystrophy (SECORD), and disorders characterized by infantile-onset or early-childhood onset closely linked to RP [13-15]. The gene discussed is RPE65; the disease is Leber congenital amaurosis.